Intellia Therapeutics Financial Statements (NTLA)
|
|
|
|
Report date
|
|
|
24.02.2022 |
23.02.2023 |
22.02.2024 |
27.02.2025 |
26.02.2026 |
|
26.02.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
33.1 |
52.1 |
36.3 |
57.9 |
67.7 |
|
67.7 |
|
Operating Income, bln rub |
|
|
-267.9 |
-458.2 |
-515.3 |
-534.3 |
-441.0 |
|
-441.0 |
|
EBITDA, bln rub |
? |
|
-261.0 |
-450.6 |
-506.3 |
-524.0 |
-396.8 |
|
-417.6 |
|
Net profit, bln rub |
? |
|
-267.9 |
-474.2 |
-481.2 |
-519.0 |
-412.7 |
|
-412.7 |
|
|
OCF, bln rub |
? |
|
-225.0 |
-333.3 |
-394.1 |
-348.9 |
-348.9 |
|
-394.7 |
|
CAPEX, bln rub |
? |
|
12.8 |
58.4 |
14.0 |
5.78 |
5.78 |
|
1.13 |
|
FCF, bln rub |
? |
|
-237.8 |
-391.7 |
-408.1 |
-354.7 |
-354.7 |
|
-395.9 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
294.0 |
502.7 |
542.6 |
581.9 |
492.7 |
|
423.7 |
|
Cost of production, bln rub |
|
|
6.89 |
7.57 |
8.98 |
10.3 |
15.9 |
|
85.0 |
|
R&D, bln rub |
|
|
229.8 |
420.0 |
435.1 |
466.3 |
388.9 |
|
388.9 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
1 294 |
1 520 |
1 301 |
1 191 |
842.1 |
|
842.1 |
|
Net Assets, bln rub |
? |
|
1 040 |
1 236 |
1 050 |
872.0 |
671.4 |
|
671.4 |
|
Debt, bln rub |
|
|
74.0 |
130.7 |
115.3 |
210.2 |
93.3 |
|
93.3 |
|
Cash, bln rub |
|
|
748.7 |
1 193 |
912.2 |
601.5 |
449.9 |
|
449.9 |
|
Net debt, bln rub |
|
|
-674.7 |
-1 062 |
-796.9 |
-391.3 |
-356.6 |
|
-356.6 |
|
|
Ordinary share price, rub |
|
|
118.2 |
34.9 |
30.5 |
11.7 |
8.99 |
|
14.1 |
|
Number of ordinary shares, mln |
|
|
70.9 |
77.0 |
88.8 |
98.8 |
108.4 |
|
108.4 |
|
|
Market cap, bln rub |
|
|
8 383 |
2 686 |
2 707 |
1 153 |
974 |
|
1 527 |
|
EV, bln rub |
? |
|
7 708 |
1 624 |
1 910 |
761 |
618 |
|
1 170 |
|
Book value, bln rub |
|
|
1 040 |
1 236 |
1 050 |
872 |
671 |
|
671 |
|
|
EPS, rub |
? |
|
-3.78 |
-6.16 |
-5.42 |
-5.25 |
-3.81 |
|
-3.81 |
|
FCF/share, rub |
|
|
-3.35 |
-5.09 |
-4.60 |
-3.59 |
-3.27 |
|
-3.65 |
|
BV/share, rub |
|
|
14.7 |
16.1 |
11.8 |
8.82 |
6.20 |
|
6.20 |
|
|
EBITDA margin, % |
? |
|
-789.5% |
-864.5% |
-1 396% |
-905.3% |
-586.3% |
|
-617.1% |
|
Net margin, % |
? |
|
-810.5% |
-909.8% |
-1 327% |
-896.8% |
-609.9% |
|
-609.9% |
|
FCF yield, % |
? |
|
-2.84% |
-14.6% |
-15.1% |
-30.8% |
-36.4% |
|
-25.9% |
|
ROE, % |
? |
|
-25.8% |
-38.4% |
-45.8% |
-59.5% |
-61.5% |
|
-61.5% |
|
ROA, % |
? |
|
-20.7% |
-31.2% |
-37.0% |
-43.6% |
-49.0% |
|
-49.0% |
|
|
P/E |
? |
|
-31.3 |
-5.66 |
-5.62 |
-2.22 |
-2.36 |
|
-3.70 |
|
P/FCF |
|
|
-35.3 |
-6.86 |
-6.63 |
-3.25 |
-2.75 |
|
-3.86 |
|
P/S |
? |
|
253.6 |
51.5 |
74.6 |
19.9 |
14.4 |
|
22.6 |
|
P/BV |
? |
|
8.06 |
2.17 |
2.58 |
1.32 |
1.45 |
|
2.27 |
|
EV/EBITDA |
? |
|
-29.5 |
-3.60 |
-3.77 |
-1.45 |
-1.56 |
|
-2.80 |
|
Debt/EBITDA |
|
|
2.59 |
2.36 |
1.57 |
0.75 |
0.90 |
|
0.85 |
|
|
R&D/CAPEX, % |
|
|
1 802% |
719.3% |
3 111% |
8 070% |
6 730% |
|
34 443% |
|
|
CAPEX/Revenue, % |
|
|
38.6% |
112.0% |
38.6% |
9.98% |
8.54% |
|
1.67% |
|
| Intellia Therapeutics shareholders |
